BioCardia Says Emory University Enrolling Heart Patients for CardiAMP HF II Trial

MT Newswires Live
04-12

BioCardia (BCDA) said Friday that Emory University School of Medicine in Atlanta has started enrolling patients with ischemic heart failure in the company's ongoing phase 3 CardiAMP HF II trial.

The CardiAMP HF II therapy is a system designed for the harvest, processing and minimally invasive delivery of autologous mononuclear cells to the heart intended to enhance microvascular density and reduce fibrosis, the company said.

The study will compare treatment with CardiAMP therapy to a placebo procedure with all patients on stable guideline directed medical therapy, the company said.

Price: 1.95, Change: +0.02, Percent Change: +1.19

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10